|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-12-22
|
|
pubmed:abstractText |
To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
pubmed-author:BarronLorettaL,
pubmed-author:BatchelorTracy TTT,
pubmed-author:BlackPeter MPM,
pubmed-author:CiampaAbigailA,
pubmed-author:DavidKarlyK,
pubmed-author:DohertyLisaL,
pubmed-author:DrappatzJanJ,
pubmed-author:KesariSantoshS,
pubmed-author:LafrankieDebra ConradDC,
pubmed-author:NordenAndrewA,
pubmed-author:OstrowskyLouisL,
pubmed-author:RamakrishnaNarenN,
pubmed-author:SceppaChristineC,
pubmed-author:SchiffDavidD,
pubmed-author:SmithSharon TST,
pubmed-author:WeissStephanieS,
pubmed-author:WenPatrick YPY,
pubmed-author:WongEric TET,
pubmed-author:ZimmermanJenniferJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
222-7
|
|
pubmed:meshHeading |
pubmed-meshheading:18513880-Adult,
pubmed-meshheading:18513880-Aged,
pubmed-meshheading:18513880-Antineoplastic Agents,
pubmed-meshheading:18513880-Brain Neoplasms,
pubmed-meshheading:18513880-Combined Modality Therapy,
pubmed-meshheading:18513880-Dose-Response Relationship, Drug,
pubmed-meshheading:18513880-Female,
pubmed-meshheading:18513880-Glioblastoma,
pubmed-meshheading:18513880-Humans,
pubmed-meshheading:18513880-Male,
pubmed-meshheading:18513880-Middle Aged,
pubmed-meshheading:18513880-Pilot Projects,
pubmed-meshheading:18513880-Thalidomide,
pubmed-meshheading:18513880-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
|
|
pubmed:affiliation |
Center for Neuro-Oncology, Dana Farber/Brigham & Women's Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
